Medipost to acquire 8.0% stake in US unit MEDIPOST, Inc. for ₩20.0bn
Medipost filed to acquire 15,000,000 shares of MEDIPOST, Inc. (US) for ₩20.0bn, equal to 8.0% of equity. After the deal, Medipost's stake will be 100.0%, with the acquisition expected on Nov 30, 2026, to fund R&D and operating costs for the US Phase 3 clinical trial and commercialization of 'Cartistem' for knee osteoarthritis.
Key facts
| Target company | MEDIPOST, Inc. (US) |
|---|---|
| Shares | 15,000,000 shares |
| Deal amount | ₩20.0bn |
| % of equity | 8.0% |
| Stake after | 100.0% |
| Purpose | Additional capital contribution for R&D costs of the US Phase 3 clinical trial and operating funds for the US commercialization of 'Cartistem', a stem cell therapy for knee osteoarthritis |
| Expected date | Nov 30, 2026 |
Comparison
| Amount as % of FY2025 revenue (calculated) | 27.2% |
|---|---|
| Revenue 2025 | ₩73.7bn |
| Revenue 2024 | ₩70.7bn |
| Revenue 2023 | ₩68.6bn |
Context
By our calculation, the amount equals 27.2% of FY2025 revenue.
Source: DART (Financial Supervisory Service) · Original filing on DART ↗